ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis rejiggers R&D organization

by Michael McCoy
October 10, 2016 | APPEARED IN VOLUME 94, ISSUE 40

[+]Enlarge
Credit: Novartis
Novartis’s headquarters site in Basel will get new R&D teams.
Credit: Novartis
Novartis’s headquarters site in Basel will get new R&D teams.

Novartis is cutting jobs and making other changes in its R&D organization as part of a research centralization strategy. The company’s sites in Cambridge, Mass., and Basel will together house a new team called Chemical Biology & Therapeutics as well as biologic therapy research centers. Biologic units in Shanghai and Schlieren, Switzerland, will close. Novartis will relocate the Novartis Institute for Tropical Diseases from Singapore to Emeryville, Calif., where it will be colocated with an infectious diseases research team. In all, about 185 jobs will be lost, but at least 60 others will be created, the firm says.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment